Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The medication is also licensed for weight management in adolescents aged 12 years and above with body weight above 60 kg and obesity
The key risks across both compounds include: Gastrointestinal adverse events (nausea, vomiting, diarrhoea), most pronounced during dose escalation Potential for gallbladder disease, consistent with rapid weight reduction Retatrutide-specific: dysesthesia and elevated resting heart rate [3] Both compounds: risk of hypoglycaemia when used in combination with insulin or sulphonylureas in diabetic models All compounds available through Sempica are strictly for research use by qualified professionals
Asia 5 (1), 469471
Support from medical professionals and effective treatment options like prescription weight loss programs can make a big difference
Semapen is a UK-based provider of expert-led weight loss programmes, including options that harness the latest injectable weight loss medications
US$ 22.82
US$ 21.91
US$ 27.82
US$ 28.03
